Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder

Neurobiology of Disease

Volumn 44, Issue 2, 2011, Pages 248-258

  Bychkov, E R ^a   Ahmed, M R ^a   Gurevich, V V ^a   Benovic, J L ^b   Gurevich, E V ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Arrestin; G protein coupled receptor kinase; MRNA expression; Postmortem; Protein expression; RNAse protection assay; Schizoaffective disorder; Schizophrenia

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; BENZATROPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; FLUPHENAZINE DECANOATE; G PROTEIN COUPLED RECEPTOR KINASE; HALOPERIDOL; ISOPROTEIN; LORAZEPAM; LOXAPINE; MESORIDAZINE; MESSENGER RNA; MIRTAZAPINE; OLANZAPINE; PERPHENAZINE; PHENYTOIN; QUETIAPINE; RETINA S ANTIGEN; RISPERIDONE; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; ARTICLE; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HUMAN; HUMAN TISSUE; MALE; MOLECULAR MECHANICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ARRESTINS; COHORT STUDIES; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 3; G-PROTEIN-COUPLED RECEPTOR KINASE 5; G-PROTEIN-COUPLED RECEPTOR KINASES; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 80052279155     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.07.009     Document Type: Article

References (75)

1. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 2007, 78:133-164.
2. Abi-Dargham A., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 2002, 22:3708-3719.
3. Ahmed M.R., et al. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by L-DOPA treatment. J. Neurochem. 2008, 104:1622-1636.
4. Ahmed M.R., et al. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J. Pharmacol. Exp. Ther. 2008, 325:276-283.
5. Ahmed M.R., et al. Lentiviral overexpression of GRK6 alleviates L-DOPA-induced dyskinesia in experimental Parkinson's disease. Sci. Transl. Med. 2010, 2:28ra28.
6. Arriza J.L., et al. The G-protein-coupled receptor kinases bARK1 and bARK2 are widely distributed at synapses in rat brain. J. Neurosci. 1992, 12:4045-4055.
7. Attramadal H., et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J. Biol. Chem. 1992, 267:17882-17890.
8. Avissar S., et al. Beta-arrestin-1 levels: reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. Am. J. Psychiatry. 2004, 161:2066-2072.
9. Baracskay K.L., et al. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 2006, 60:271-279.
10. Beaulieu J.M., et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
11. Benovic J.L., Gomez J. Molecular cloning and expression of GRK6. A new member of the G protein-coupled receptor kinase family. J. Biol. Chem. 1993, 268:19521-19527.
12. Bezard E., et al. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 2005, 18:323-335.
13. Bohn L.M., et al. Enhanced morphine analgesia in mice lacking beta-arrestin2. Science 1999, 286:2495-2498.
14. Bohn L.M., et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408:720-723.
15. Bohn L.M., et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J. Neurosci. 2003, 23:10265-10273.
16. Brennan A.R., et al. Protein kinase C activity is associated with prefrontal cortical decline in aging. Neurobiol. Aging. 2007, 30:782-792.
17. Bychkov E., et al. Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol. Aging. 2008, 29:379-396.
18. Chan T.O., et al. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem. 1999, 68:965-1014.
19. Colantuoni C., et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct. Funct. 2008, 213:255-271.
20. Craddock N., Owen M.J. The beginning of the end for the Kraepelinian dichotomy. Br. J. Psychiatry. 2005, 186:364-366.
21. Craddock N., et al. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J. Med. Genetics. 2005, 42:193-204.
22. Craddock N., et al. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 2006, 32:9-16.
23. Deep-Soboslay A., et al. Psychiatric brain banking: three perspectives on current trends and future directions. Biol Psychiatry. 2010, 69:104-112.
24. Eckhart A.D., et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ. Res. 2000, 86:43-50.
25. Feighner J.P., et al. Diagnostic criteria for use in psychiatric research. Arch. Gen. Psychiatry 1972, 26:57-63.
26. Gainetdinov R.R., et al. Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 1999, 24:1029-1036.
27. Gainetdinov R.R., et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 2003, 38:291-303.
28. Gainetdinov R.R., et al. Desensitization of G protein-coupled receptors and neuronal function. Ann. Rev. Neurosci. 2004, 27:107-144.
29. García-Sevilla J.A., et al. Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. Eur. Neuropsychopharmacol. 2010, 20:721-730.
30. Goldsmith S.K., et al. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 1997, 54:649-658.
31. Gurevich V.V., Gurevich E.V. The new face of active receptor bound arrestin attracts new partners. Structure 2003, 11:1037-1042.
32. Gurevich E.V., Gurevich V.V. Arrestins: ubiquitous regulators of cellular signaling pathways. Genome Biol. 2006, 7:236.
33. Gurevich V.V., Gurevich E.V. Rich tapestry of GPCR signaling and regulatory mechanisms. Mol Pharm. 2008, 74:312-316.
34. Gurevich E.V., et al. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 2002, 109:421-436.
35. Gurevich E.V., et al. Arrestin2 expression selectively increases during neural differentiation. J. Neurochem. 2004, 91:1404-1416.
36. Hamshere M.L., et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch. Gen. Psychiatry 2005, 62:1081-1088.
37. Hao J., et al. Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys. J. Neurosci. 2006, 26:2571-2578.
38. Iaccarino G., et al. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am. J. Physiol. 1998, 275:1298-1306.
39. Iaccarino G., et al. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 1998, 98:1783-1789.
40. Iwata K., et al. Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2. J. Biol. Chem. 2005, 280:2197-2204.
41. Kim C.M., et al. Expression and characterization of two beta-adrenergic receptor kinase isoforms using the baculovirus expression system. Receptor 1993, 3:39-55.
42. Kim K.M., et al. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J. Biol. Chem. 2001, 276:37409-37414.
43. Kim J., et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc. Nat. Acad. Sci. U. S. A. 2005, 102:142-1447.
44. Koch W.J., et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995, 268:1350-1353.
45. Koh P.O., et al. Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch. Gen. Psychiatry 2003, 60:311-319.
46. Koh P.O., et al. Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:313-317.
47. Kohout T.A., et al. Beta-arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1601-1606.
48. Kunapuli P., et al. Expression, purification, and characterization of the G protein-coupled receptor kinase GRK5. J. Biol. Chem. 1994, 269:1099-1105.
49. Levenson R., et al. Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends Pharmacol. Sci. 2003, 24:486-492.
50. Lewis D.A., González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008, 33:141-165.
51. Loudon R.P., Benovic J.L. Expression, purification, and characterization of the G protein-coupled receptor kinase GRK6. J. Biol. Chem. 1994, 269:22691-22697.
52. Luo J., et al. M3 muscarinic acetylcholine receptor-mediated signaling is regulated by distinct mechanisms. Mol. Pharmacol. mol 2008, 107:044750.
53. Macey T.A., et al. Preferential interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Mol. Pharmacol. 2004, 66:1635-1642.
54. Macey T.A., et al. Dopamine D1 receptor interaction with arrestin3 in neostriatal neurons. J. Neurochem. 2005, 93:128-134.
55. Morris H.M., et al. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb. Cortex. 2008, 18:1575-1587.
56. Mundell S.J., et al. Characterization of G protein-coupled receptor regulation in antisense mRNA-expressing cells with reduced arrestin levels. Biochemistry 1999, 38:8723-8732.
57. Naik S., et al. Regulation of cysteinyl leukotriene type 1 receptor internalization and signaling. J. Biol. Chem. 2005, 280:8722-8732.
58. Oakley R.H., et al. Differential affinities of visual arrestin, barrestin1, and barrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 2000, 275:17201-17210.
59. Orsini M.J., Benovic J.L. Characterization of dominant negative arrestins that inhibit beta-2-adrenergic receptor internalization by distinct mechanisms. J. Biol. Chem. 1998, 273:34616-34622.
60. Pan L., et al. The nature of the arrestin x receptor complex determines the ultimate fate of the internalized receptor. J. Biol. Chem. 2003, 278:11623-11632.
61. Parruti G., et al. Molecular analysis of human beta-arrestin-1: cloning, tissue distribution, and regulation of expression. Identification of two isoforms generated by alternative splicing. J. Biol. Chem. 1993, 268:9753-9761.
62. Premont R.T., et al. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J. Biol. Chem. 1994, 269:6832-6841.
63. Ramos B.P., et al. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 2003, 40:835-845.
64. Ren X.R., et al. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1448-1453.
65. Richardson M.A., et al. Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder. Neurochem. Res. 2007, 32:107-113.
66. Rockman H.A., et al. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9954-9959.
67. Scarr E., Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. J. Neurochem. 2008, 107:1188-1195.
68. Schmauss C. Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia. J. Neurosci. 1996, 16:7902-7909.
69. Schmid C.L., Bohn L.M. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J. Neurosci. 2010, 30:13513-13524.
70. Schmid C.L., et al. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1079-1084.
71. Sterne-Marr R., et al. Polypeptide variants of beta-arrestin and arrestin3. J. Biol. Chem. 1993, 268:15640-15648.
72. Tamminga C.A., Davis J.M. The neuropharmacology of psychosis. Schizophr. Bull. 2007, 33:937-946.
73. Waas W.F., et al. Two rate-limiting steps in the kinetic mechanism of the serine/threonine specific protein kinase ERK2: a case of fast phosphorylation followed by fast product release. Biochemistry 2003, 42:12273-12286.
74. Willets J.M., et al. Imaging of muscarinic acetylcholine receptor signaling in hippocampal neurons: evidence for phosphorylation-dependent and -independent regulation by G-protein-coupled receptor kinases. J. Neurosci. 2004, 24:4157-4162.
75. Willets J.M., et al. The regulation of M1 muscarinic acetylcholine receptor desensitization by synaptic activity in cultured hippocampal neurons. J. Neurochem. 2007, 103:2268-2280.